Form 4: Enanta Pharmaceuticals Executive Forfeits Shares to Cover Taxes

Paul J. Mellett, Chief Financial and Administrative Officer of Enanta Pharmaceuticals, forfeited 1,595 shares of common stock to cover withholding taxes.

Summary

• Paul J. Mellett, the Chief Financial and Administrative Officer of Enanta Pharmaceuticals, forfeited 1,595 shares of common stock on December 1, 2024.
• The shares were forfeited to cover withholding taxes due from the settlement of restricted stock unit awards granted in 2020 and 2021.
• Following the transaction, Mr. Mellett directly owns 94,301 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a neutral event related to standard executive compensation practices and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Stock forfeitures to cover tax obligations are a standard practice in the pharmaceutical industry and other sectors where stock-based compensation is common.
• Many companies use restricted stock units as part of their compensation packages, and the resulting tax liabilities often lead to similar transactions.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also regularly report similar transactions by their executives.

Stakeholder Impact

• The transaction has a minor impact on the total number of outstanding shares, but is not expected to significantly affect shareholders.
• The transaction is part of the executive compensation package and is not expected to impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Enanta Pharmaceuticals, stock forfeiture, insider transaction, Form 4, executive compensation, restricted stock units, withholding taxes